Pfizer makes money the same way it always has: by discovering medicines and vaccines, winning government approval to sell them, and then collecting revenue every time a doctor prescribes one or a government buys a dose. The company sells to wholesalers, hospitals, pharmacies, and directly to governments in roughly 200 countries. Its biggest products today include Eliquis, a blood-clot medicine co-marketed with Bristol-Myers Squibb; the Prevnar family of vaccines that protect against serious bacterial infections; the Vyndaqel family for a rare heart disease called amyloidosis; and a growing oncology portfolio anchored by Ibrance, Padcev, and Xtandi. Pfizer also still earns meaningful revenue from Paxlovid, its COVID-19 treatment pill, and Comirnaty, its COVID-19 vaccine developed with BioNTech. The diagram below traces where the money goes.
Five years of financial data tell a story with a very clear shape: a pandemic-driven boom, a sharp collapse, and an uncertain rebuilding. In 2021, revenue was $73.6 billion. In 2022, it surged to $92.6 billion as governments around the world paid top dollar for Comirnaty and Paxlovid. Then demand for COVID products fell off a cliff.
Revenue has stabilised since the crash, reaching $55.2 billion in 2024 and $53.3 billion in 2025, but it has not returned anywhere near its peak. The more encouraging signal is in gross margin, which measures how much money is left after the basic cost of making the products. Gross margin actually improved from about 52 percent in 2023 to nearly 70 percent in 2025, suggesting the non-COVID product mix is more profitable than the pandemic era suggested.
Cash generation tells a more sobering story. Free cash flow, the money left over after the company pays its bills and spends on equipment, was $29.9 billion in 2021 and $26.0 billion in 2022. By 2023 it had fallen to $4.8 billion. It recovered slightly to $9.8 billion in 2024 and $9.1 billion in 2025, but that is still less than a third of the peak. The debt taken on for the Seagen acquisition sits at $63.7 billion in net debt as of 2025, and servicing that debt consumes cash that could otherwise fund research or dividends.
Pfizer faces several documented threats that are not speculative. They are already written into law or already visible in the competitive landscape. The most important is patent expiration. Between 2026 and 2030, several of the company's biggest revenue earners will lose their legal protection from copycat competition. Pfizer's own filings say this revenue loss will accelerate significantly over the next few years. In 2026 alone, the impact is expected to be $1.5 billion.
On top of patent cliffs, the United States government is now directly setting prices for some of Pfizer's most important drugs. A law called the Inflation Reduction Act allows Medicare, the government health program for older Americans, to negotiate maximum prices for certain medicines. Eliquis, Pfizer's single biggest product at 13 percent of total 2025 revenue, already had its government-set price take effect in January 2026. Ibrance and Xtandi face the same process starting in 2027, and Xeljanz is next in 2028. More products could be added in future years.
There is also pressure from the Trump Administration. In September 2025, Pfizer agreed voluntarily to make some drug prices for American patients more comparable to prices in other countries, and to let patients buy certain medicines at significant discounts through a government platform called TrumpRx.gov. In exchange, Pfizer's products are protected from a specific type of import tax called Section 232 tariffs for three years, as long as Pfizer keeps investing in American manufacturing. Pfizer's filings note that the final binding version of this agreement could still contain unfavorable terms, and tariffs could still apply if conditions are not met.
Generic competition from China adds a further layer of difficulty. Pfizer's filings specifically name Chinese generic manufacturers as companies that have cut prices and taken market share from Pfizer products, particularly in China itself, which was Pfizer's largest single market outside the United States in both 2024 and 2025 at roughly 4 to 5 percent of total revenues.
Pfizer's leadership has been clear about the challenge ahead. The company's stated priority is to invest to maximise growth after 2028, which is the period when the worst of the patent expirations and government price-setting decisions are expected to hit. The pipeline includes cancer drugs, weight management treatments, vaccines, and medicines for rare diseases. About $500 million in research and development savings achieved through a cost-cutting programme in 2025 is expected to be reinvested into research programmes in 2026. The question is whether that pipeline can produce enough approved, commercially successful medicines to fill the gap.
Pfizer is running a cost-cutting programme in parallel. The company launched a multi-year cost realignment effort in late 2023 and expanded it in 2025, targeting savings across sales, marketing, research, and manufacturing. It is also scaling artificial intelligence across its business to improve efficiency. These moves are meant to protect profits while revenue is under pressure, but they do not by themselves solve the revenue problem.